Related Experiment Video
Updated: May 27, 2026
09:21
Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
Published on: January 18, 2018
Idraparinux and idrabiotaparinux
1Clinical Pharmacology, Faculty of Medicine Mannheim, Ruprecht-Karls University Heidelberg, Maybachstrasse 14, D-68169 Mannheim, Germany. job.harenberg@medma.uni-heidelberg.de.
Expert Review of Clinical Pharmacology
|November 25, 2011
Summary
Idraparinux showed similar efficacy for deep vein thrombosis but less for pulmonary embolism, and increased bleeding risk, leading to development halt. Idrabiotaparinux is under investigation for preventing recurrent venous thromboembolism (VTE) and embolic events.
Area of Science:
- Pharmacology
- Thrombosis Research
Background:
- Idraparinux is a synthetic pentasaccharide targeting antithrombin.
- Idrabiotaparinux is a biotinylated derivative of idraparinux.
Purpose of the Study:
- Evaluate idraparinux and idrabiotaparinux efficacy and safety in VTE and atrial fibrillation.
- Assess long-term prophylaxis and bleeding risks associated with idraparinux.
Main Methods:
- Clinical data review of idraparinux and idrabiotaparinux up to April 2009.
- Comparison of idraparinux with enoxaparin and warfarin for VTE treatment and prophylaxis.
- Evaluation of idraparinux in atrial fibrillation patients for embolic event prevention.
Main Results:
- Idraparinux was nearly as effective as enoxaparin/warfarin for deep vein thrombosis but less for pulmonary embolism.
- Prolonged idraparinux prophylaxis for recurrent VTE was more effective but caused severe bleeding.
- Idraparinux showed similar efficacy to warfarin for atrial fibrillation but with increased major bleeding.
- Idraparinux's long elimination half-life (60 days) correlated with bleeding complications, leading to its discontinuation.
Conclusions:
- Idraparinux development was stopped due to safety concerns, primarily severe bleeding.
- Idrabiotaparinux is currently being investigated for preventing recurrent VTE and embolic events in clinical trials.
- The future of idrabiotaparinux hinges on demonstrating safety and efficacy, alongside avidin's role in its administration.
Related Concept Videos
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:17Drugs for Treatment of Diarrhea-Predominant IBS
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
01:29Drug Delivery: Parenteral Route
The parenteral route is a critical method of drug administration. It delivers compounds directly into the systemic circulation and bypasses the gastrointestinal tract. This approach is particularly advantageous for drugs that exhibit poor absorption or instability when administered orally.
There are three primary parenteral routes: intravenous (IV), intramuscular (IM), and subcutaneous (SC). The IV route introduces the drug directly into the bloodstream, ensuring immediate action. The IM route...
There are three primary parenteral routes: intravenous (IV), intramuscular (IM), and subcutaneous (SC). The IV route introduces the drug directly into the bloodstream, ensuring immediate action. The IM route...